November 9, 2010 – In an effort to further promote the utility of PET/CT (positron emission tomography/computed tomography) imaging in assessing the effectiveness of oncology treatments, a new quantification tool is available to support PERCIST (PET response criteria in solid tumors). PERCIST provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Since the introduction of PERCIST, Siemens Healthcare Molecular Imaging created a PET/CT quantification tool to aid in the adoption of PERCIST evaluation criteria. Using a consistent PET protocol and fixed small region of interest, Siemens’ quantification tool evaluates the most active region of a metabolically active tumor to minimize statistical variability and offer the most consistent results. Siemens supports industry initiatives with this software tool that will make PERCIST data available and reproducible for every patient, so that these criteria will be clinically adopted and used in the field.

RECIST is a well established set of rules for determining response to therapy for patients. These criteria were formed on the basis of measuring anatomical changes in tumors using CT imaging. Because PET/CT imaging can detect changes to the tumor at the molecular level, thought leaders in the molecular imaging field introduced PERCIST criteria to use together with RECIST.

While RECIST criteria offer quantifiable data in terms of tumor size, the PERCIST quantification tool creates reproducible, objective results based on metabolic information for tumor trending over time to determine the efficacy of treatment. PERCIST criteria allow treatment response to be measured in the absence of anatomic change through the assessment of metabolic activity, often even before anatomical changes take place. The PERCIST quantification tool evaluates and delineates metabolic information from the tumor. The tool uses an algorithm that automatically identifies peak SUV within a volume of interest, rather than the common single-pixel measure of SUVmax. The PERCIST quantification tool offers a more robust metric that is less susceptible to statistical variation and noise.

For more information: www.siemens.com/healthcare


Related Content

News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
News | Radiology Business

April 17, 2024 — VISTA.AI announced the appointment of Daniel Hawkins as President and CEO. The company is pioneering AI ...

Time April 17, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
News | ACR

April 15, 2023 — The American College of Radiology (ACR) released an update to its ACR Appropriateness Criteria (ACR AC) ...

Time April 13, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Therapy

April 12, 2024 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery, and ...

Time April 12, 2024
arrow
Subscribe Now